Band 24, Supplement 5, September 2001
S. Pistorius, W. E. Berdel, Teresa Padró(Instituto de Salud Carlos III), Stefan Post(University of Mannheim), Rüdiger Hehlmann(Heidelberg University), J Kienast(University of Münster), M.E. Heim, F. Wenz, Martin Steins(Heidelberg University), Dirk Schadendorf(National Center for Tumor Diseases), Georgia Metzgeroth(Heidelberg University), M. Neises, Grit Faulmann, G. Hartung, H.-D. Saeger, U. Tiefenbacher, T. Lahaye, Agata Musiał, P. Alken(Heidelberg University), Matthias Löhr(Karolinska University Hospital), H. Flechtner, Klaus‐Josef Weber, Roderich Bönninghoff, U. Berger, Michael Keese, S. Kreil, Tobias Keßler(German Cancer Research Center), Joseph B. Weiss(University of North Carolina Health Care), M. Wüstner, S. Retzlaff, Hans K. Schackert(Technische Universität Dresden), J. Sturm, Manfred V. Singer, M. Siegsmund, F. Hummel, F. Willeke, Ralf Bieker, A. Hochhaus
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k